| Variable | Edoxaban 30 mg | Edoxaban 60 mg | Reference | Dabigatran 110 mg bid | Dabigatran 150 mg bid | Reference [5] | Rivaroxaban | Reference [5] | Apixaban | Reference [5] |
| Quality of life estimates (utility) | | | | | | | | | | | NOAC | 0.994 (0.975–1.00) | 0.994 (0.975–1.00) | [12, 13, 16, 18] | 0.994 (0.975–1.00) | 0.994 (0.975–1.00) | [12, 13, 16, 18] | 0.994 (0.975–1.00) | [12, 13, 16, 18] | 0.994 (0.975–1.00) | [12, 13, 16, 18] | Warfarin | 0.987 (0.953–1.00) | 0.987 (0.953–1.00) | [12, 16, 18] | 0.987 (0.953–1.00) | 0.987 (0.953–1.00) | [12, 16, 18] | 0.987 (0.953–1.00) | [12, 16, 18] | 0.987 (0.953–1.00) | [12, 16, 18] | Neurological sequelae | | | | | | | | | | | Mild | 0.87 (0.00–1.00) | 0.87 (0.00–1.00) | [21] | 0.87 (0.00–1.00) | 0.87 (0.00–1.00) | [21] | 0.87 (0.00–1.00) | [21] | 0.87 (0.00–1.00) | [21] | Moderate | 0.68 (0.00–1.00) | 0.68 (0.00–1.00) | [21] | 0.68 (0.00–1.00) | 0.68 (0.00–1.00) | [21] | 0.68 (0.00–1.00) | [21] | 0.68 (0.00–1.00) | [21] | Serious | 0.52 (0.00–1.00) | 0.52 (0.00–1.00) | [21] | 0.52 (0.00–1.00) | 0.52 (0.00–1.00) | [21] | 0.52 (0.00–1.00) | [21] | 0.52 (0.00–1.00) | [21] | Recurrent event | 0.12 (0.00–1.00) | 0.12 (0.00–1.00) | [13] | 0.12 (0.00–1.00) | 0.12 (0.00–1.00) | [13] | 0.12 (0.00–1.00) | [13] | 0.12 (0.00–1.00) | [13] | Myocardial infarction | 0.5 (0.00–1.00) | 0.5 (0.00–1.00) | Assumption [12, 20] | 0.5 (0.00–1.00) | 0.5 (0.00–1.00) | Assumption [12, 20] | 0.5 (0.00–1.00) | Assumption [12, 20] | 0.5 (0.00–1.00) | Assumption [12, 20] | Hemorrhage | | | | | | | | | | | Major hemorrhage | 0.85 (0.00–1.00) | 0.85 (0.00–1.00) | Assumption [12, 19, 22] | 0.85 (0.00–1.00) | 0.85 (0.00–1.00) | Assumption [12, 19, 22] | 0.85 (0.00–1.00) | Assumption [12, 19, 22] | 0.85 (0.00–1.00) | Assumption [12, 19, 22] | Minor hemorrhage | 0.95 (0.00–1.00) | 0.95 (0.00–1.00) | [12, 18] | 0.95 (0.00–1.00) | 0.95 (0.00–1.00) | [12, 18] | 0.95 (0.00–1.00) | [12, 18] | 0.95 (0.00–1.00) | [12, 18] |
|
|